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CancerAdiponectin (APN), an adipokine, exerts an anti-inﬂammatory and anti-cancerous activity with its role in
glucose and lipid metabolism and its absence related to several obesity related malignancies including
colorectal cancer. The aim of this study is to determine the effect of APN deﬁciency on the chronic
inﬂammation-induced colon cancer. This was achieved by inducing inﬂammation and colon cancer in both
APN knockout (KO) and C57B1/6 wild type (WT) mice. They were divided into four treatment groups
(n=6): 1) control (no treatment); 2) treatment with three cycles of dextran sodium sulfate (DSS); 3) weekly
doses of 1,2-dimethylhydrazine (DMH) (20 mg/kg of mouse body weight) for twelve weeks; 4) a single dose
of DMH followed by 3 cycles of DSS (DMH+DSS). Mice were observed for diarrhea, stool hemoccult, and
weight loss and were sacriﬁced on day 153. Tumor area and number were counted. Colonic tissues were
collected for Western blot and immunohistochemistry analyses. APNKO mice were more protected than
WT mice from DSS induced colitis during ﬁrst DSS cycle, but lost this protection during the second and the
third DSS cycles. APNKO mice had signiﬁcantly severe symptoms and showed greater number and larger
area of tumors with higher immune cell inﬁltration and inﬂammation than WT mice. This result was further
conﬁrmed by proteomic study including pSTAT3, pAMPK and Cox-2 by western blot and Immunohistochem-
istry. Conclusively, APN deﬁciency contributes to inﬂammation-induced colon cancer. Hence, APN may play
an important role in colorectal cancer prevention by modulating genes involved in chronic inﬂammation
and tumorigenesis.
© 2011 Elsevier B.V. All rights reserved.1 Abbreviations: AC, Aberrant crypt; ACF, Aberrant crypt foci; AMPK, Adenosine
mono-phosphate kinase; ANOVA, Analysis of variance; APN, Adiponectin; APNKO,
Adiponectin knockout; CD, Crohn's disease; CICC, Chronic inﬂammation-induced colon
cancer; COX, Cyclooxygenase; DMH, Dimethylhydrazine; DSS, Dextran sodium sulfate;1. Introduction
Patients with inﬂammatory bowel disease, such as Crohn's and
ulcerative colitis (UC), are at increased risk for developing colorectal
cancer [1,2]. UC patients, in particular, have ten to forty fold increased
risk of developing cancer, compared with the general population
[3,4]. The pathogenesis of colitis-associated colorectal cancer is
thought to be related to an increased rate of epithelial cell prolifera-
tion associated with the repetitive cycles of inﬂammation, damage
and regeneration [5,6]. In addition, obesity, an established risk factor
for colorectal cancer, is characterized by the accumulation of exces-
sive adipose tissue, which is the source of a variety of biologically
active substances, collectively referred to as adipokines [7,8]. Adipo-
nectin (APN), an adipokine secreted by the adipose tissue, has been
found at low levels in obese subjects [9,10]. Obesity and APN have
been linked to colon cancer by various studies [11–15]. Furthermore;
obesity is associated with a heightened inﬂammatory response in+1 803 777 0558.
rights reserved.Crohn's disease (CD) patients who have typical alterations of mesen-
teric fat deposits [16].
Adiponectin exerts its activity through its receptors. Two recep-
tors, AdipoR1 and AdipoR2, had been identiﬁed for APN and were
found to mediate glucose and fatty acid metabolism by Adenosine
mono-phosphate kinase (AMPK) activation, although no mechanism
has been devised for its activation [17–20]. 1AMPK is a serine threo-
nine kinase, which is activated by phosphorylation, in the presence
of cellular stress [21,22]. AMPK has anti-inﬂammatory effects and
has been considered as a potential therapeutic target for cancer
[23–26]. APN increases the rate of phosphorylation of AMPK and sup-
presses cell growth by inhibiting the mammalian target of rapamycinELISA, Enzyme linked immunosorbent assay; GAPDH, Glyceraldehyde-3-phosphate
dehydrogenase; H&E, Hematoxylin and eosin; HRP, Horseradish peroxidase; IL, Inter-
leukin; iNOS, Nitric oxide synthase; mTOR, Mammalian target of rapamycin; SDS-
PAGE, Sodium dodecyl sulphate-polyacrylamide gel electrophoresis; STAT, Signal
transducer and activator of transcription; TNF, Tumor necrosis factor; UC, Ulcerative
colitis; WT, Wild type.
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ase (Cox)-2, an enzyme that is upregulated in the presence of various
stimuli like inﬂammation, tumorigenesis, metastasis, and growth fac-
tors [24,25]. More importantly, APN has been linked to reduce expres-
sion of Cox-2 in APNKO mice treated with azoxymethane [26].
Signal transducer and activator of transcription (STAT)-3 is over-
expressed in many cancers and is a potent indicator of inﬂammation
[27]. It plays a critical role in tumor progression and metastasis
through transcriptional activation of anti-apoptotic genes like Bcl-xL,
Mcl-1 and survivin, cell-cycle regulators (e.g. cyclin D1 and c-Myc)
and inducers of angiogenesis (e.g. vascular endothelial growth factor)
[28,29].
In this paper, we have used dextran sodium sulphate (DSS), a
potent inducer of inﬂammation and promoter of colorectal carcino-
genesis. It was administered in mice for three cycles to induce chronic
inﬂammation, while dimethylhydrazine (DMH) was injected intra-
peritoneally to induce cancer. APN knockout (KO) and the C57Bl/6
wild type (WT) mice were given different treatments to elucidate
the role of APN deﬁciency in chronic inﬂammation-induced colon
cancer (CICC).
We hypothesized that APNKO mice are more susceptible to CICC
as compared to their WT counterpart, which could be deduced by
greater weight loss, bloody stools, diarrhea, larger number and size
of the tumors. It is also evident by the up-regulation of pro-
cancerous and downregulation of anti-cancerous and inﬂammatory
genes.
2. Materials and methods
2.1. Animals and experimental groups
Six to eight week old male APNKO (n=24) and male C57BL/6
(WT, n=24) were housed in conventional animal room and treated
in the animal facility at the University of South Carolina. All APNKO
mice were homozygous for APN deﬁciency (−/−). The mice were on
a 12:12 h light–dark cycle in a low stress environment (22 °C, 50%
humidity and low noise) and had access to food (Purina Chow) and
water ad libitum. All animal care followed institutional guidelines
under a protocol approved by the Institutional Animal Care and Use
Committee at the University of South Carolina. APNKO and WT mice
were randomly assigned to 4 different groups of equal number
(n=6 mice per group): 1) DMH+DSS; 2) DMH; 3) DSS and 4) Con-
trol or no treatment. The body weight of both APNKO and WT mice
showed no signiﬁcant difference at the beginning of the study.
2.2. Induction of chronic inﬂammation and cancer
Chronic inﬂammation was induced in the WT and APNKO mice
assigned to the DSS treatment group. These mice received 2% dextran
sodium sulfate (DSS) (MP Biochemicals, MW: 36,000–50,000) dis-
solved in their drinking water for ﬁve days, followed by ﬁve days of
regular drinking water, this represented single cycle and DSS was
administrated for three cycles on days 4, 27 and 50. To establish
chronic inﬂammation induced colon cancer, another group of mice
received 3 cycles of DSS and a single injection of DMH intraperitone-
ally (i.p) (SIGMA ALDRICH) (20 mg/kg body weight) administered at
the beginning of the DSS treatment. Cancer was induced in the WT
and APNKO mice assigned to DMH treatment group by administering
weekly dose of DMH i.p. for twelve weeks and the mice were sacri-
ﬁced on day 153.
2.3. Monitoring animal health
Mice were observed daily for clinical signs of disease attributed by
weight loss, fecal hemoccult and diarrhea during all treatments and
till day 153. Ranking for the weight loss was based on the followingscale: 0 = 0–5% weight loss; 1 = 6–10% weight loss; 2 = 11–15%
weight loss; 3 = 16–20% weight loss; and 4 = >20% weight loss.
The appearance of diarrhea was scored as: 0 = well-formed pellets,
2 = pasty and semi-formed stools that do not adhere to the anus,
4 = liquid stools that adhere to the anus. Appearance of blood in
the stools was assessed using a hemoccult kit (BECKMAN COULTER)
and scored as: 0 = no blood, 2 = positive hemoccult, 4 = gross
bleeding. The clinical score was then determined by totaling the
weight loss, hemoccult, and diarrhea scores with the highest score
being twelve.
2.4. Tissue collection and tumor quantiﬁcation
The mice were euthanized by cervical dislocation. The colon was re-
moved and ﬂushed with PBS containing 5000 IU/mL and 5000 IU/mL
penicillin and streptomycin (CELLGRO) respectively. Two 2 mm2 sec-
tions of the descending colon were dissected and stored at−80 °C for
Western blot analysis and at 37 °C, 5% CO2 with overnight incubation
for tissue culture. The remaining colon was ﬁxed in 10% formalin
(AZER SCIENTIFIC) for a day. It was then stained with 0.2% methylene
blue (FISHER SCIENTIFIC) to count tumors and measure tumor area fol-
lowed by its swiss roll and sectioning it for immunohistochemistry and
Hematoxylin and Eosin (H&E) staining. Tumor quantiﬁcation was done
in blinded condition by two individuals.
2.5. Colonic cytokines and serum APN measurement
The secreted concentrations (pg/mg of protein) of IL-6, IL-10, IL-
1β and TNF-α in the tissue culture were determined by Enzyme
Linked Immunosorbent Assay (ELISA) using BD OptEIA kit (BD
BIOSCIENCES). Serum APN was determined in all the treatment
groups at the beginning and at the end of the study. This was
achieved by diluting the serum samples to 1:2000 and performing
ELISA using DuoSet mouse/Acrp30 kit (R&D SYSTEMS).
2.6. Protein determination and western blot
Tissues frozen at −80 °C were thawed and homogenized in RIPA
buffer (SIGMA) containing 1:1000 dilution of protease inhibitor solu-
tion (SIGMA). Concentration of the total protein in the solution of
homogenized tissue was calculated by Bradford protein assay. Protein
homogenate from each group was loaded and electrophoresed on
10% SDS-PAGE gels and transferred to a nitrocellulose membrane at
constant voltage of 200 mA for 150 min at 4 °C. The membrane was
then blocked with 5% non-fat dry milk (BIO-RAD) in DPBS (cellgro)+
0.1% Tween 20 (BIO-RAD) for one hour at room temperature followed
by overnight incubation at 4 °C with STAT3 and pSTAT3 (1:000) (CELL
SIGNALING TECHNOLOGY), AMPK and pAMPK (1:1000) (SANTA CRUZ
BIOTECHNOLOGY) and GAPDH (1:3000) (R&D SYSTEM) diluted in
DPBS+0.1% Tween 20. Membrane was subsequently washed 5 times
for 10 min with DPBS+0.1% Tween 20 with consequent incubation
with anti-rabbit or anti goat secondary antibody conjugatedwith horse-
radish peroxidase enzyme (1:3000) (SANTA CRUZ BIOTECHNOLOGY)
for 1 h. The membrane was washed and incubated for 5 min in Amer-
sham ECL Plus Western blot detection system (GE HEALTHCARE) with
subsequent detection on high performance chemiluminescence ﬁlm
(Amersham Hyperﬁlm ECL, GE HEALTHCARE). GAPDH was used as a
loading control to normalize the protein expression by densitometry
using Image J software (NCBI). Western blot for each protein was
done thrice by using all samples from the same treatment group to
determine statistical signiﬁcance.
2.7. Immunohistochemical staining
Serial tumor and non tumor sections of mouse colon tissues were
incubated with antibodies against cyclooxygenase-2 (Cox-2; rabbit
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staining and reproducible results, sections were incubated by slow
rocking overnight in primary antibodies (4 °C) using the Antibody
Ampliﬁer (ProHisto, LLC). Following incubation with primary anti-
body, sections were processed using EnVision+System-HRP kit
(DAKO CYTOMATION). The chromogen was 3,3′-diaminobenzidine
and sections were counterstained with 0.5% methyl green. The posi-
tive control tissue was colon cancer sections which were highly pos-
itive for iNOS, Cox-2, TNF-α, p53, and p53-phospho-Ser15.
Stained tissues were examined for intensity of staining using a
method similar to that previously described by Nishihara et al. [30].
Brieﬂy, intensity of staining in colon sections was evaluated indepen-
dently by two blinded investigators. For each tissue section, the
summation of the intensity of staining and the percentage of the pos-
itively stained cells was analyzed and quantiﬁed on a scale of 4, where
0 represents no staining, 2 — 50–75% of moderately stained cells, and
4 indicates more than 75% of darkly stained cells. All the images were
taken in 20X magniﬁcation with Nikon e600 microscope. The scale
bar represents 120 μm.
2.8. Hematoxylin and Eosin staining and histological scoring
To determine the pathological state of the colon, a standard proto-
col for H&E staining was used. Quantiﬁcation of severity of disease
including inﬂammation and immune cell inﬁltration was done on
the scale of 4 for both the parameters, where 0 = no inﬁltration or
no inﬂammation; 2 = moderate inﬁltration or inﬂammation; and
4 = severe inﬂammation with distorted crypts or inﬁltration and
formation of lymphatic follicles. All the images were taken in 20×
magniﬁcation with Nikon e600 microscope. The scale bar represents
120 μm.
2.9. Aberrant crypt foci (ACF)
The H&E stained slides for DSS treated groups for APNKO and WT
were scanned by two investigators in the blinded conditions for aber-
rant crypt foci. The ratio of the number of ACF to normal crypts was
calculated in the 2 mm2 area and was plotted on a graph. All the
images were taken in 40× magniﬁcation with Nikon e600 micro-
scope. The scale bar represents 60 μm.
2.10. Statistical analysis
Two-way analysis of variance (ANOVA), Two-way repeated
measure ANOVA and One-way ANOVA was used to analyze the data
with Tukey post hoc-analyses . A p valueb0.05 was considered statis-
tically signiﬁcant. All the statistical analyses were done by using
SigmaStat 3.5 (SPSS, Chicago, IL).
3. Results
3.1. Clinical manifestation of CICC in APNKO and WT mice
To study the role of APN deﬁciency in CICC, WT and APNKO mice
were given three different treatments and were observed for weight
loss, diarrhea and hemoccult for 153 days and during this time clini-
cal score was calculated. After the ﬁrst DSS cycle in DSS and DSS+
DMH group, WT mice lost their protection from DSS in comparison
to APNKO mice and showed a signiﬁcantly higher clinical score on
day 18 in DSS group (Fig. 1B and C). However, no signiﬁcance was
observed in DSS+DMH group. After the second DSS cycle, APNKO
mice manifested signiﬁcantly higher clinical score on days 32, 34
and 36 when treated with DSS alone, but in DSS+DMH treatment
group, it was observed on day 29 (Fig. 1B and C). Following the
third DSS cycle, there was a complete loss of protection from DSS in
the DSS and DSS+DMH group resulting in a signiﬁcantly higherclinical score in APNKO mice as compared to WT mice (Fig. 1B and
C). Mice in DSS+DMH group didn't recover from the treatment and
the clinical score continued to remain signiﬁcantly higher in APNKO
mice till the date of sacriﬁce (Fig. 1C). DSS treated mice recovered
after every DSS cycle but after the third cycle, APNKO mice showed
a comparatively higher clinical score than WT (data not shown). In
DMH treatment group, signiﬁcantly higher clinical score was ob-
served in APNKO mice when compared to WT mice on days 77, 105
and 128, after which the score continued to remain higher till the
date of sacriﬁce (Fig. 1A).
3.2. Tumor development in APNKO and WT mice
Immediately following the sacriﬁce, mice colon was ﬁxed and
stained in methylene blue for tumor quantiﬁcation (Fig. 2A). APNKO
mice had a signiﬁcantly greater tumor number than WT mice in all
the treatment groups (Fig. 2A and B). The degree of signiﬁcance was
higher in DMH group, but the number of tumors was higher in DSS+
DMH group as compared to others. In DSS+DMH group, APNKO mice
showed a signiﬁcantly larger tumor area as compared to the WT
group (Fig. 2C). Most of the tumors were observed in the descending
and the rectal part of the colon.
3.3. Colon morphology
To study the change in the colon morphology in CICC, H&E stain-
ing for all the treatment groups was done for both WT and APNKO
mice and quantiﬁed on a scale of one to four. It was observed that
the APNKO mice treated with DSS+DMH showed a complete loss
of structural integrity of the colon epithelium. Inﬁltration of the im-
mune cells was also observed in addition to crypt destruction.
Tumor growth was more prominent and the number of tumors was
observed to be greater in APNKO mice than WT in DSS+DMH
group (Fig. 3A). APNKO mice treated with DSS+DMH had signiﬁ-
cantly severe immune cell inﬁltration, inﬂammation and distorted
crypts as compared to WT mice (Fig. 3B). Signiﬁcance in the severity
of inﬂammation and inﬁltration was also observed in APNKO mice
treated with DMH (H&E not shown). DSS treated group showed no
signiﬁcant difference between the APNKO and WT mice (Fig. 3B).
DSS treated group however showed a signiﬁcantly higher ACF in the
APNKO mice as compared to WT mice (Fig. 3C and D). Other treat-
ment groups were observed for ACF, but neither showed ACF as
they have developed tumors or the observed difference was not sig-
niﬁcant between the APNKO and WT mice.
3.4. Systemic APN in WT mice and secreted cytokine proﬁling for all the
treatment groups
To determine the effect of different treatments on the systemic
APN levels, sera were obtained from the WT mice at the beginning
of the study or pre-treatment and at the time of sacriﬁce. It was
observed that the serum APN concentration in DSS+DMH treated
group was signiﬁcantly less when compared to the WT mice treated
with DSS or DMH alone and with the control group (Fig. 4E). DMH
treated mice showed a signiﬁcantly lower concentration of serum
APN than the DSS alone and control group. Signiﬁcant decrease in
the serum APN level was observed in the DSS+DMH and DMH
alone treated WT mice on days 153 and 0 (Fig. 4E). However no sig-
niﬁcant difference was found in the mice treated with DSS and the
control group (Fig. 4E).
The tissue culture media was then used to perform secreted cyto-
kine proﬁling and the concentration of the secreted IL-6, IL-10, TNF-α
and IL-1β was calculated in all the treatment groups by using ELISA.
APNKO mice showed a signiﬁcantly higher colonic IL-6 and TNF-α
levels in DSS and DSS+DMH groups when compared to the WT
mice (Fig. 4A and D). IL-1β, another pro-inﬂammatory cytokine was
Fig. 1. Clinical score of DSS and DMH treatments. (A–C) Clinical score for DMH, DSS and DSS+DMH was plotted against the different time point during the study. The arrows rep-
resent the days of DSS administration in DSS and DSS+DMH study groups. The score was calculated out of twelve points; four points for each weight loss, diarrhea and hemoccult.
Two-way repeated measure analysis of variance (ANOVA) was applied to calculate the signiﬁcant difference between the clinical score for APNKO and WT mice thought the length
of the experiment. **pb0.05, #pb0.001, *pb0.03.
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mice in DMH and DSS+DMH group (Fig. 4C). IL-10, grouped as an
anti-inﬂammatory cytokine was quantiﬁed and it was found that in
all the treatment groups, was a signiﬁcant decrease in APNKO mice
with greater signiﬁcance in the DSS+DMH group as compared to
WTmice. IL-10 level in APNKOmice of DSS+DMH group was compa-
rable to the baseline untreated control group (Fig. 4B).
3.5. Colonic STAT3, AMPK, and Cox-2 expression
We investigated the effect of APN deﬁciency on various pathways
involved in inﬂammation and colon cancer in our different treatment
groups. We observed signiﬁcantly higher expression levels of
pSTAT3Ser727 and Cox-2 in APNKO mice treated with DSS+DMHand DMH in comparison to WT mice. However, no signiﬁcant differ-
ence was observed in the expression level of APNKO andWTmice ad-
ministered with DSS alone (Fig. 5A, B and D). No to minimum
expression of pSTAT3Ser727 was detected in control group (Fig. 5A
and B). However, low expression of Cox-2 was observed in APNKO
mice in control group while there was no expression in WT mice
(Fig. 5A and D). p-AMPK-α ½Thr 172 was downregulated and signiﬁ-
cantly decreased expression in APNKO mice treated with DSS+
DMH and DSS alone in comparison to the WT mice. Comparatively,
higher expression of p-AMPK-α ½Thr 172 was observed in control
group (Fig. 5A and C). GAPDH was used as a loading control and was
used to normalize all the protein density measurements (Fig. 5A).
Ratio of the phosphorylated protein to full protein was represented on
the graph.
Fig. 2. Tumor development in APNKO and WT mice treated with DSS and DMH. (A) Colon of WT and APNKO mice treated with DSS+DMH and stained with 0.2% methylene blue.
(B) Average number of tumors counted per mice per group for all the treatments in order of their severity. (C) Average tumor area in mm2 counted for each mouse per group plot-
ted in the order of their severity. One-way ANOVA was used to calculate signiﬁcant difference between APNKO and WT mice given the same treatment for all the experimental
groups. *pb0.05 and # pb0.03.
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After proteomic study by Western blot, localization of Cox-2 was
determined, by immunohistochemistry for Cox-2 antigen in the
tumor and the non tumor area of the descending colon section of
both APNKO and WT mice. This study revealed signiﬁcantly higher
expression of Cox-2 in the tumor area than the non tumor area ofFig. 3. Hematoxylin and Eosin staining and aberrant crypt foci. (A) H&E stained sections of
bar=120 μm). (B) Quantiﬁcation of inﬂammation and immune cell inﬁltration in all the tre
of the APNKO and WT mice treated with DSS alone and observed and marked for Aberrant c
calculating the ratio of the aberrant crypts to the normal crypts. Degree of signiﬁcance was
*pb0.05 and # pb0.01.the mice treated with DSS+DMH, irrespective of mice genotype
(Fig. 6A, B and C). APNKO mice also showed signiﬁcantly higher
expression of Cox-2 when compared with WT mice treated with
DSS+DMH (Fig. 6A, B and C). Signiﬁcant difference was also found
in APNKO mice of the tumor and the non tumor group and most im-
portantly between the APNKO and the WT mice treated with DSS+
DMH in the tumor group (Fig. 6A, B and C). However, the Cox-2the descending colon of KO and WT mice in DSS group with 20× magniﬁcation (scale
atment groups on a scale of four. (C) H&E stained slides of the descending colon section
rypt foci with 40× magniﬁcation (scale bar=60 μm). (D) Quantiﬁcation of the ACF by
calculated by One-way ANOVA between the KO and WT of the same treatment group.
Fig. 4. Cytokine secretion from the colon of APNKO and WT mice. (A-D) Amount of IL-6, IL-10, Il-1β and TNF-α secreted respectively from the colon of the APNKO and WT mice
subjected to treatment of DSS, DMH and DSS+DMH and to the control group. (E) Serum adiponectin levels (μg/mL) in WT mice treated with DSS+DMH, DMH alone, DSS
alone and control group at days 0 and 153. Signiﬁcant difference was observed in the serum adiponectin level of the WT mice treated with DSS+DMH and DMH alone, DSS
alone and control group, and WT mice treated with DMH and DSS alone and control group. Signiﬁcant difference was also observed within the DSS+DMH and DMH alone
group at days 0 and 153. One way ANOVA was applied to calculate the signiﬁcant difference between the secretion of cytokine from APNKO and WT mice belonging to the
same group. *pb0.01,**pb0.04, ***pb0.02, #pb0.05.
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treated with DSS+DMH in the non tumor sections and other treat-
ment group including DSS alone and DMH alone group with no
expression in untreated groups (Fig. 6A, B and C).
4. Discussion
Protective role of APN in obesity, cancer and other disease models
has been established but, in this paper, we have tried to delineate its
function in the CICC, which is a common condition in patients suffer-
ing from IBD and have been the second leading cause of cancer death
in the United States [31]. This study was primarily designed to deduce
the effect of APN deﬁciency on the physical and molecular attributes
of CICC. Our results showed a signiﬁcantly severe clinical manifesta-
tion in the APNKO mice treated with DSS+DMH after the third DSS
cycle. It continued to remain severe till the date of sacriﬁce. However
there was no signiﬁcant difference observed after the ﬁrst and second
DSS cycles. This observation is in accordance with common diseased
state observed during colon cancer and could be explained by the
loss of protection in the colonic epithelium of APNKO mice treated
with DSS and DMH in chronic conditions. Absence of APN made the
mice more vulnerable to DSS induced colitis and DMH inducedcolon cancer. Our group has shown that in acute phase in WT mice,
this effect was not prominent as APN binds to growth factors like
HB-EGF, bFGF that prevents the renewal of the colonic epithelium
and hence there was no signiﬁcant difference between the clinical
score of APNKO and WT mice treated with DSS+DMH [32]. This
paper adds another chapter in APN research on the much-debated
topic of APN as an anti-inﬂammatory or pro-inﬂammatory adipokine.
Our results show a peculiar behavior of APN deﬁciency that has an
anti-inﬂammatory effect in acute phase and a pro-inﬂammatory enti-
ty in chronic condition and colon cancer. Nishihara et al. [30] showed
signiﬁcant weight loss in the APNKO mice treated with AOM than WT
mice; however we followed a more comprehensive approach and
combined weight loss with diarrhea and hemoccult.
DSS+DMH treated group was found to show the highest number
of tumors and tumor areas. A signiﬁcant difference was found be-
tween the WT and APNKO mice for both area and number of tumors.
This observation could be explained by the results of Brakenhielm et
al. [33], where they proved APN to induce anti-angiogenesis and to
perform anti-tumor activity involving caspase- mediated endothelial
cell apoptosis. DSS and DMH alone groups also showed a signiﬁcant
difference in the tumor number between the WT and APNKO. Most
of the tumors observed were in the descending and the rectal portion
Fig. 5. Protein expression of STAT3, pSTAT3, AMPK, pAMPK, COX-2 in APNKO and WT mice under different treatment conditions. A) Western blot representing the expression of
STAT3, pSTAT3, AMPK, pAMPK, COX-2 and GAPDH. B–D) Graphs showing the ratio of the relative density of the bands for pSTAT3/STAT3 (B), p-AMPK/AMPK (C) and COX-2
(D) being normalized by GAPDH, for control and three other treatments in the order of their severity in WT and APNKO mice. ANOVA was used to determine the signiﬁcant
difference between APNKO and its wild counter parts for all the treatments. * pb0.03, **pb0.05, #pb0.02.
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was also found to be enlarged and more number of tumors was ob-
served in the APNKO mice as compared to WT (data not shown).
However, no metastasis was found in the lungs and liver. These data
are in agreement with our previous observations and provide an in-
sight about the role of APN in tumor development with absence of
APN being a risk factor for chronic colonic inﬂammation and colitis.
It also follows the same pattern as counted by Nishihara et al. [30].
Ferroni et al. [34] had regarded lower serum APN as an adjunctive
prognosis for the risk of colorectal cancer. Likewise, we found signif-
icantly decreased level of serum APN in the DSS+DMH treated WT
mice as compared to control and along the length of the experiment
(days 0 and 153). This indicates an inverse relation between the
APN and CICC and could be attributed to greater chronic inﬂamma-
tion and cancer growth [35]. A study conducted by Karmiris et al.
showed signiﬁcantly elevated APN levels in UC patients [36]. On the
contrary, we observed no signiﬁcant difference in the APN level of
the WT mice treated with DSS and control and also during the length
of the experiment. This disparity could be due to that most of the UC
patients received 5-aminosalicylic acid, which has been shown to in-
crease PPAR-γ expression, which in turn increases APN production
[37]. In addition, the DSS model that we used is not an ideal model
for UC. This protective role of APN was further strengthen by our his-
tological evidences which indicates signiﬁcantly greater formation of
ACF in APNKO mice treated with DSS as compared to WT mice, which
has been debated by several pathologist as a diagnostic tool for colon
cancer. We conﬁrmed the results obtained by Fujisawa et al. [38] in-
dicating signiﬁcantly higher ACF and aberrant crypt in APNKO under
high fat diet condition. However, we obtained the same results
under normal diet with DSS treatment. Further exploration was
done by quantiﬁcation of inﬂammation and immune cell inﬁltration
in DSS+DMH group, which was found to be signiﬁcantly higher inthe APNKO mice. Tumors could be histologically observed in the
APNKO mice treated with DSS+DMH. Higher inﬁltration of the im-
mune cells and greater inﬂammation, epithelial cell disruption and
formation of the primary and secondary lymphatic follicles were
common sightings, which is a clear indication of greater colon epithe-
lium insults in APNKO mice when compared to WT.
Adipose tissues have been linked to the secretion of several pro-
inﬂammatory cytokines and APN has been proved to play an impor-
tant role in regulating their secretion by downregulating the auto-
crine release of adipose tissue derived pro-inﬂammatory cytokines
like IL-6, IL-8 from macrophages [39,40]. Our results indicate similar
ﬁnding with signiﬁcantly higher secretions of pro-inﬂammatory
cytokines like IL-6, IL-1β and TNF-α and reduced secretion of anti-
inﬂammatory cytokines like IL-10 in the descending colon section of
the APNKO mice treated with DSS+DMH as compared to WT mice.
IL-6 and TNF-α was also found to show signiﬁcantly higher level in
the APNKOmice treated with DSS while IL-1βwas found to show sig-
niﬁcantly higher level in APNKO mice treated with DMH while IL-10,
an anti-inﬂammatory cytokine, level was signiﬁcantly downregulated
in the same group. Higher secretion of TNF-α was observed in the
DSS-treated than DSS+DMH-treated APNKOmice, but the difference
was not signiﬁcant. This could be explained by the multifunctional
roles of this cytokine in apoptosis, cell survival and inﬂammation
[41]. Although some investigators argue that the higher TNF-α levels
are associated with tumorigenesis but at the same time, TNF-α is a
well know pyrogen that induce apoptotic cell death and acts synergis-
tically with cytostatic drugs in cancer treatments [41,42]. Lower
levels of TNF-α in DSS+DMH treated APNKO mice directly correlate
with greater tumor number and size. Higher TNF-α production in DSS
treated APNKOmice could be primarily due to the greater secretion of
TNF-α by macrophages and lymphocytes due to chronic inﬂamma-
tion [43,44], delayed recovery from the third DSS cycle and the
Fig. 6. Cox-2 immunohistochemical staining and quantiﬁcation. (A) Immunohistochemical staining for Cox-2 (brown) in the non tumor area of the descending colon (2 mm2) sec-
tion of control, DSS, DMH and DSS+DMH treated groups in both WT and KO mice. (B) Immunohistochemical staining for Cox-2 (brown) in the tumor area of the descending colon
(2 mm2) section of DSS+DMH treated groups in both WT and KO mice. (C) Quantiﬁcation of the Cox-2 expression in the non tumor descending colon 2 mm2 section of the WT and
KO mice treated with DSS, DMH, DSS+DMH and control group and DSS+DMH group in the tumor area. Two-way ANOVA was used for statistical signiﬁcance. # versus
‡ (pb0.002), † and * versus § and ** (pb0.002), § versus **(pb0.002), * versus ** (pb0.002).
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tory condition [45]. However, these mechanisms are remained to be
investigated. These data provide a link between the absence of APN
and higher production of pro-inﬂammatory cytokines and decrease
production of anti-inﬂammatory cytokines under the conditions in-
cluding cancer, inﬂammation and CICC. This might be regarded as
the ﬁrst direct inﬂuence of the APN deﬁciency on CICC.
To further investigate the role of the APN deﬁciency in CICC, we
searched deeper in to the protein expression especially targeting
the key pathways involved in cancer and inﬂammation. Our main
focus lies on the JAK/STAT signaling pathways, followed by phosphor-
ylation of AMPK, which is directly correlated with the major protein
synthesis, mTOR pathway. Phosphorylation of the STAT3 was found
to be up-regulated in oppose of AMPK phosphorylation in the
APNKO mice treated with DSS+DMH. This indicates higher inﬂam-
mation and reduction in the energy state milieu andmight be the rea-
son for slower recovery. This up-regulation of JAK/STAT3 signaling
pathway could be mediated by IL-6 and regulated by SOCS3 signaling
[46,47]. However, partial hepatectomy or liver regeneration studies
showed reduced expression of phosphorylated STAT3 with the con-
comitant increase in SOCS3 mRNA in APN null mice [46]. This vari-
ability could be accounted to the variable SOCS3 mediatedactivation pattern of STAT3, during different time points along the
length of the study. Another explanation could be the variable roles
of APN that may play in different tissues and disease models. Higher
STAT3 expression was observed in the control group as compared to
DSS treated groups, which could be attributed to the constitutive ex-
pression of STAT3. However, only the activated or the phosophoryla-
tion of the protein could be affected by the diseased state. This was
followed by another investigation of the Cox-2 expression, which
plays multiple roles in oncogenesis, metastasis and inﬂammation re-
lated to cancer. Cox-2 was found to be over-expressed in the
APNKO mice treated with DSS+DMH and DMH alone. However in
heart ischemia model, APN was found to increase the expression of
Cox-2 [48]. This provides another evidence of the multifaceted nature
of adiponectin. By the means of Cox-2 expression studies, we con-
ﬁrmed the results of Nishihara et al. [30], but in our CICC model we
went a step further to investigate localized expression of Cox-2 in
tumor and non tumor area by immunohistochemistry. Cox-2 was
found to be signiﬁcantly over-expressed in tumor area of the colon
as compared to non tumor area, which could be due to the combined
effect of the overexpression of cancer epithelial cells in addition to the
localized secretion by inﬂammatory mononuclear cells, ﬁbroblast and
vascular endothelial cells. However the majority of the intensity and
Fig. 7. A hypothetical model showing the effect of APN deﬁciency in chronic inﬂammation induced colon cancer. In CICC, APN deﬁciency aggravates the inﬂammatory condition by
increased expression of pro-inﬂammatory molecule like STAT3 and cytokines like IL-6, TNF-α and IL-1β and reduced production of anti-inﬂammatory molecules like pAMPK and
cytokines like IL-10. It also results in higher ACF presence, which subsequently leads to adenocarcinoma. APN deﬁciency in CICC increased Cox-2 expression in the epithelial cells
with the highest been found in the tumor area. This might be a potential mechanism of Cox-2, which inhibits apoptosis mediated by Bcl-2 that regulates the release of cytochrome c
from mitochondria with further inhibition of caspases.
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[49,50]. In APNKO mice treated with DSS+DMH, Cox-2 expression
was found to be the highest and signiﬁcantly greater than WT mice
in the tumor area. This approach was also instrumental in studying
the histopathology of the colon, which was found to show a complete
disruption of the tissue architecture in the tumor area along with the
formation of the primary lymphoid follicle.
Although, our study established a link between the absence of APN
and its effects on the molecular and physical attributes of CICC, with
its absence linked with higher expression of pro-inﬂammatory and
pro-cancerous markers, it did not illustrate the direct role of APN in
CICC. To deﬁne the function of APN in our model system, our future
work will be to reconstitute APN in all the treatment groups and
observe its role during the same timeline. It could also be suggested
to further explore the role of APN in apoptotic pathways and establish
the interplay of APN in other molecular and cellular pathways by the
application of whole genome microarray. Further characterization of
APN isoforms could also result in clinical applications.
5. Conclusion
The novelty of this work encompasses several ﬁndings including
the anti-inﬂammatory condition in the state of APN deﬁciency during
the ﬁrst DSS cycle, an acute phase of inﬂammation. However, in the
second and the third DSS cycles, the chronic inﬂammation, APNKO
mice lost their protection and showed a higher clinical score reﬂect-
ing upon the pro-inﬂammatory role of APN deﬁciency. APNKO mice
were found to have greater number of tumors and tumor area with
marked inﬂammation and inﬁltration in CICC as compared to WT
mice given the same treatment. APNKO mice treated with DSS+
DMH have signiﬁcantly higher expression of pSTAT3 and Cox-2 and
downregulation of pAMPK. Cox-2 was found to be localized in signiﬁ-
cantly higher amount and intensity in the colon tumor area of the
APNKO mice as compared to the WT mice treated with DSS+DMH.
In conclusion, we propose a model to deﬁne the effects of APN deﬁ-
ciency in CICC (Fig. 7). These ﬁndings provide strong evidence for
the use of APN or a chemically analogous structure as a therapeuticcompound in decreasing the severity of the symptoms caused by
CICC and other related diseases.
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